September 20, 2020

HGH Bill Would Increase Costs and Limited Availability of Medical Treatment for Children

Filip Bondy wrote a story today about the likelihood that growth hormone would be more expensive and more difficult to obtain for parents of children with growth-related disorders as a result of a Congressional bill that would reclassify human growth hormone as a controlled substance (“Littlest victims of an HGH bill,” March 17).

Here’s the problem: The proposed legislation would re-classify HGH as a Schedule III drug, increasing penalties for its illegal use and limiting access in several ways. The penalties are fine, the parents agree. Limiting access for growth-challenged kids is the deal breaker.

The Champs, for example, would need to go to Mount Sinai Hospital in Manhattan once every month for a new prescription, which would last 30 days. Currently with each visit, they are able to obtain a three-month supply of HGH, with two refills. They only need to go once every nine months. Meanwhile, their insurance co-pays would triple for the extra doses.

[Read more…]